Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function.
about
The Janus kinases (Jaks)SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptorJanus kinases in immune cell signalingTYK2 is a key regulator of the surveillance of B lymphoid tumorsBasal ubiquitin-independent internalization of interferon alpha receptor is prevented by Tyk2-mediated masking of a linear endocytic motifTherapeutic targeting of Janus kinasesTyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytesA natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunityIntegrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated CancerHuman TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndromeA novel transactivating factor that regulates interferon-gamma-dependent gene expressionTyrosine kinase inhibitors for the treatment of rheumatoid arthritisTYK2 kinase activity is required for functional type I interferon responses in vivoTyk2 and Stat3 regulate brown adipose tissue differentiation and obesityA Critical Role for the Type I Interferon Receptor in Virus-Induced Autoimmune Diabetes in Rats.JAK and MPL mutations in myeloid malignancies.Transcriptome analysis reveals a major impact of JAK protein tyrosine kinase 2 (Tyk2) on the expression of interferon-responsive and metabolic genes.Allelic variation in the Tyk2 and EGF genes as potential genetic determinants of CNS repair.Tyrosine kinase 2 promotes sepsis-associated lethality by facilitating production of interleukin-27The molecular regulation of Janus kinase (JAK) activationRole of Tyk-2 in Th9 and Th17 cells in allergic asthma.Impact of microbes on autoimmune diseases.Contribution of the Box 1 and Box 2 motifs of cytokine receptors to Jak1 association and activation.Tyrosine kinases in inflammatory dermatologic disease.Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.Genetic susceptibility to Candida infections.Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitisThe tyrosine kinase Tyk2 controls IFNAR1 cell surface expression.JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age.Cytokines and immunodeficiency diseases.Series introduction. JAK-STAT signaling in human disease.Investigational Janus kinase inhibitors.An epidermotypic model of interface dermatitis reveals individual functions of fas ligand and gamma interferon in hypergranulosis, cytoid body formation, and gene expression.IL-20: a new target for the treatment of inflammatory skin disease.The role of Tyk2 in regulation of breast cancer growth.Reduced Tyk2 gene expression in β-cells due to natural mutation determines susceptibility to virus-induced diabetes.The role of signal transducers and activators of transcription in T inflammatory bowel diseases.Targeting the Jak/STAT pathway for immunosuppression.
P2860
Q21194856-44EBE79D-4041-4EFF-9254-4F7A5308E74BQ24297139-72CB87BE-0AC1-4456-BE20-E61AE727778DQ24322021-47A1A310-0011-4730-8248-DF2D4FEBE4C6Q24559982-F1B34D50-AC8B-4BC4-8CB3-4570D7D135DCQ24649769-E1D53253-AAB5-44FB-B54A-E464C6B72691Q24658483-2D104D1E-309D-4205-A0F3-99015B4CA016Q24672330-D3368DC6-A5DB-4A4E-864B-6F7A3AB10DB5Q24673016-8FFB8C5D-68C1-492F-88DB-9595BB736ECFQ26764757-32C47A2D-864F-4922-AFCE-19EF18693B77Q28266613-56C69D21-6CD0-4A1C-B1D3-78F607FAE51EQ28588598-90A88FD8-5FA4-46AB-940F-6D99B6B36475Q28674280-AD345A00-224F-499E-A004-B28144057952Q28728338-147DF2B3-3A11-488F-9E21-F64D55059B40Q30415923-D0DCD02F-9055-4286-BCA0-793A837E703BQ31812554-969B6D0A-7AA1-4E69-BD2A-A1BD9AC04FA0Q33378737-7FD6479B-1CA8-4B09-BCA2-CF99FC16627DQ33546127-DB15B2E6-1CE7-482C-8A58-063F69B607D4Q33640136-9D62116F-DE5D-4244-BF9B-1EBA0BD65636Q33750852-928CBEF5-3032-4970-A574-2AC2C7076C50Q33956113-223CE852-8BB6-43AD-BF7A-4E17E371717DQ34023371-A6F57E2C-8C31-476D-8E52-9ECE2DE1AC04Q34053306-23DF9DA4-F0E5-4CFA-86D4-71934E8C760FQ34153995-41111347-2586-4031-82F4-4CB984BFB063Q34166503-1FED886F-CE5B-4169-ADB4-FD370B6AE7EFQ34169114-096D1B56-9A6D-4D14-95B6-BE9DE47C8108Q34276089-A8EDC256-5C48-4457-957F-E980AC588118Q34341908-DD405CF9-D493-4CA1-B3F5-D437B791AC56Q34386311-E6BC40C5-6F2D-4D86-BB8F-505A933F7332Q34433877-C5D6F895-8A2D-4C3C-81D1-E60F7C3176B6Q34463632-D6ABEBD1-1C55-4E6A-9564-3072BA3A8932Q34502049-0419E360-0B05-48B7-B24E-4D8E87FD02CCQ34572193-40B6AAA8-85E9-4DFF-BB59-D5882F207B07Q34627060-00C720D5-436B-4EE3-B17F-238AAD5F95CAQ34648724-1E987E25-77E9-4CFF-83CB-7AEC8AD03B72Q34843615-81321574-64AB-43ED-B0DA-9D62226964ADQ35095128-A26CE108-886E-4A16-A5BC-6C8B35C9F948Q35214992-A4DA7CE3-FDDF-4B2F-BF61-F3BA21696026Q35407467-C19C82DC-B9B1-4AC4-B37F-C80B0E7D6C71Q35558031-15F78C4C-6273-496B-8003-1AE2ED6F818CQ35579377-E76C8B55-EBA1-41D9-9E15-DCD6C50DB241
P2860
Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Tyk2 plays a restricted role i ...... L-12-mediated T cell function.
@ast
Tyk2 plays a restricted role i ...... L-12-mediated T cell function.
@en
type
label
Tyk2 plays a restricted role i ...... L-12-mediated T cell function.
@ast
Tyk2 plays a restricted role i ...... L-12-mediated T cell function.
@en
prefLabel
Tyk2 plays a restricted role i ...... L-12-mediated T cell function.
@ast
Tyk2 plays a restricted role i ...... L-12-mediated T cell function.
@en
P2093
P1433
P1476
Tyk2 plays a restricted role i ...... L-12-mediated T cell function.
@en
P2093
Kobayashi S
Miyamoto A
Nakayama K
Nakayama T
P304
P356
10.1016/S1074-7613(00)00055-8
P407
P577
2000-10-01T00:00:00Z